UHS' 21% YTD slide has cheapened its valuation, but weaker volumes, ACA pressure and lower growth forecasts keep risks elevated.
| Quartal / Datum | EPS (USD) | Schätzung (USD) | Abweichung |
|---|
| Quartal / Datum | Umsatz (Mio USD) | Schätzung (Mio USD) | Abweichung |
|---|